Sanofi

GPTKB entity

Statements (136)
Predicate Object
gptkbp:instance_of gptkb:Company
gptkbp:bfsLayer 2
gptkbp:bfsParent gptkb:physicist
gptkbp:acquired gptkb:Aventis
gptkb:Genzyme_Corporation
gptkbp:acquisition gptkb:Amunix_Pharmaceuticals
gptkb:Bioverativ
gptkb:Boehringer_Ingelheim's_animal_health_business
gptkb:Chattem
gptkb:Genzyme
gptkb:Kymab
gptkb:Medi_Gene_AG
gptkb:Provention_Bio
gptkb:Apexigen
gptkb:Sangamo_Therapeutics
gptkb:Ablynx
Translate Bio
Acquired Genzyme in 2011
gptkbp:ceo gptkb:Paul_Hudson
gptkbp:clinical_trial over 35,000
Phase 3
conducts numerous clinical trials annually
conducts clinical research in various fields
conducts clinical trials globally
gptkbp:collaborations with WHO
gptkbp:cultural_representation promotes workplace diversity
gptkbp:developed_by gptkb:drug
gptkbp:employees Approximately 100,000
around 100,000
over 100,000
gptkbp:focus Pharmaceuticals and Vaccines
gptkbp:focus_area vaccines
gptkbp:founded gptkb:2004
gptkbp:global_presence Operates in over 100 countries
operates in over 100 countries
strong global presence
gptkbp:headquarters gptkb:Paris,_France
gptkbp:healthcare prescription drugs
over-the-counter products
consumer healthcare products
https://www.w3.org/2000/01/rdf-schema#label Sanofi
gptkbp:industry gptkb:drug
gptkbp:innovation invests in innovative therapies
gptkbp:is_vulnerable_to gptkb:European_Medicines_Agency_(EMA)
2-8 degrees Celsius
protein subunit vaccine
Vidprevtyn
up to 90% in trials
gptkbp:language_of_instruction has a diverse product pipeline
gptkbp:market operates in over 100 countries
gptkbp:market_cap approximately €100 billion (2021)
€100 billion (2021)
gptkbp:operates_in gptkb:drug
over 100 countries
gptkbp:partnership gptkb:GSK
gptkb:Regeneron_Pharmaceuticals
with academic institutions
Partnership with various biotech firms
with biotech companies
GSK for COVID-19 vaccine
U. S. government for vaccine distribution
UNICEF for immunization programs
WHO for vaccine distribution
biotech companies for drug development
government agencies for public health initiatives
various academic institutions for research
gptkbp:philanthropy gptkb:Sanofi_Espoir_Foundation
gptkbp:product_line gptkb:hospital
antibiotics
nutritional products
biologics
hormonal therapies
antiviral drugs
pain relief medications
biosimilars
gene therapies
cell therapies
cardiovascular drugs
dermatology products
allergy medications
vaccines for infectious diseases
OTC allergy products
OTC children's health products
OTC cold and flu products
OTC digestive health products
OTC men's health products
OTC oral care products
OTC pain relief products
OTC skin care products
OTC vitamins and supplements
OTC women's health products
gptkbp:production_location multiple locations worldwide
gptkbp:products gptkb:Dupixent
gptkb:Company
gptkb:Lantus
Vaccines
vaccines
Oncology drugs
Cardiovascular drugs
diabetes medications
Rare disease treatments
cardiovascular medications
oncology medications
gptkbp:research gptkb:John_Francis_Reed
gptkbp:research_and_development gptkb:John_Francis_Reed
€6 billion (2020)
Invests heavily in R& D
gptkbp:research_areas gptkb:Company
vaccines
central nervous system disorders
cardiovascular diseases
infectious diseases
pain management
gptkbp:research_focus neurology
oncology
rare diseases
vaccines
immunology
gptkbp:revenue €36.1 billion (2020)
€36 billion (2020)
gptkbp:stock_exchange gptkb:Euronext_Paris
gptkbp:subsidiary gptkb:Sanofi_Genzyme
gptkb:Sanofi_Aventis
gptkb:Sanofi_Pasteur
gptkbp:sustainability committed to sustainability initiatives
gptkbp:sustainability_initiatives diversity and inclusion programs
community engagement programs
commitment to access to medicines
employee health and safety programs
focus on environmental responsibility
gptkbp:symbol gptkb:SAN
gptkbp:targets gptkb:COVID-19
gptkbp:traded_on gptkb:Euronext_Paris
gptkbp:type gptkb:Company
gptkbp:website www.sanofi.com
sanofi.com